FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir

NCT ID: NCT01777997

Last Updated: 2021-08-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 38 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-04-25
• Study Completion Date: 2017-02-07

Brief Summary

This study was done with people who were infected with HIV, but did not show any signs of having HIV. They were also feeling well without taking HIV medication and had low or undetectable levels of the virus in the blood. The purpose of this study was to see if taking HIV medication (antiretroviral therapy [ART]) would reduce immune activation (a signal that the body is fighting an infection) in people who have HIV, but did not show symptoms. Also this study helped determine how safe the drug was and how well people reacted to the drug.

For this study, the following antiretroviral therapy (ART) was be provided in the form of a single tablet that contains three different drugs: emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF). These drugs were combined as one tablet which was approved by the Food and Drug Administration (FDA) as a single pill to treat HIV infection. The HIV medication provided was one of the recommended treatments for HIV, including people with low viral loads (how much HIV you have in your body) who were taking HIV drugs for the first time. The risks seen with this HIV medication were the same that one would encounter when taking these drugs outside of the study.

Detailed Description

AIDS Clinical Trials Group (ACTG) A5308 was a single-arm clinical trial to evaluate the effect of initiating fixed-dose combination (FDC) FTC/RPV/TDF on CD8+ T-cell activation and other immunologic and virologic biomarkers among treatment-naïve HIV-1 controllers with any absolute CD4+ T-cell count. At study entry, these participants were followed off ART for a 12-week lead-in period, and then at week 12, participants initiated FDC FTC/RPV/TDF and had 48 weeks of follow-up to evaluate the primary endpoint.

All participants who completed Step 1 (48 weeks of ART) had the option to register to Step 2, for an additional 48 weeks of follow-up, and had the choice of either continuing FDC FTC/RPV/TDF or follow-up with no study treatment.

Participants underwent safety and tolerability evaluations throughout the study, including physical examinations and clinical assessments. Pregnancy tests were performed on women of childbearing potential. Collection of stored blood plasma/peripheral blood mononuclear cell (PBMC) samples occurred at entry and weeks 0, 4, 12, 24, 36, 48, 60, 72 and 96 on ART.

Only participants who were on intervention (ART) for at least 24 weeks had samples sent for testing of immunologic and virologic biomarkers.

Conditions

HIV-1 Infection

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

FTC/RPV/TDF

Group Type: EXPERIMENTAL

Emtricitabine/rilpivirine/tenofovir disoproxil fumarate

Intervention Type: DRUG

Step 1: From entry through week 12, the participants received no study treatment. From week 12 through week 60, the participants received one fixed dose combination emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) tablet daily.

Step 2 (Optional): From week 60 through week 108, the participants either received one FTC/RPV/TDF tablet daily or no study treatment.

Interventions

Emtricitabine/rilpivirine/tenofovir disoproxil fumarate

Step 1: From entry through week 12, the participants received no study treatment. From week 12 through week 60, the participants received one fixed dose combination emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) tablet daily.

Step 2 (Optional): From week 60 through week 108, the participants either received one FTC/RPV/TDF tablet daily or no study treatment.

Intervention Type: DRUG

Other Intervention Names

FTC/RPV/TDF; Complera

Eligibility Criteria

Inclusion Criteria

Step 1

• HIV-1 infection
• ART-naïve defined as ≤7 days of antiretroviral (ARV) treatment at any time prior to entry
• Documentation of HIV-1 RNA <500 copies/mL verified by at least two measurements prior to the screening RNA specimen
• Screening HIV-1 RNA <500 copies/mL using an US FDA-approved assay obtained within 60 days prior to study entry by any laboratory that has a CLIA certification or its equivalent
• Laboratory values obtained within 60 days prior to entry by any laboratory that has a CLIA certification or its equivalent:

• Absolute neutrophil count (ANC) >=500/mm^3
• Hemoglobin >=8.0 g/dL
• Platelet count >=40,000/mm^3
• Aspartate aminotransferase (AST) (SGOT), alanine aminotransferase (ALT) (SGPT), and alkaline phosphatase <=5 X Upper Limit of Normal (ULN)
• Total bilirubin <=2.5 X ULN
• Calculated creatinine clearance (CrCl) >=60 mL/min
• For females of reproductive potential, negative serum or urine pregnancy test within 48 hours prior to study entry by any clinic or laboratory that has a CLIA certification or its equivalent
• Female subjects of reproductive potential, who are participating in sexual activity that could lead to pregnancy, must agree to use at least one reliable form of contraceptive (ie, condoms (male or female) with or without a spermicidal agent; a diaphragm or cervical cap with spermicide; an intrauterine device (IUD); or hormone-based contraceptive) while receiving the protocol-specified treatment and for 6 weeks after stopping the medications
• No evidence of any exclusionary resistance mutations based on results from any genotype assay from any laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent

Step 2

• Completion of Step 1
• Ability and willingness of subject to choose to receive either open-label ART FDC (FTC/RPV/TDF) or no study treatment for an additional 48 weeks
• For females of reproductive potential, negative serum or urine pregnancy test within 48 hours prior to the week 60 visit by any clinic or laboratory that has a CLIA certification or its equivalent

Exclusion Criteria

Step 1

• Chronic hepatitis B virus (HBV) infection (documented by hepatitis B surface antigen (HBsAg) seropositivity)
• Breastfeeding
• Use of immunomodulators (eg, interleukins, interferons, cyclosporine), topical imiquimod, HIV vaccine, systemic cytotoxic chemotherapy, or investigational therapy within 30 days prior to study entry or plans to start immunomodulators, topical imiquimod, HIV vaccine, systemic cytotoxic chemotherapy, or investigational therapy during the study
• Known allergy/sensitivity or any hypersensitivity to components of study drug(s) or their formulation
• Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements
• Acute or serious illness requiring systemic treatment and/or hospitalization within 30 days prior to entry
• Symptomatic HIV disease and/or AIDS-defining illness.
• Vaccinations within 7 days prior to study entry
• Plans to initiate hepatitis C treatment during the study
• Perinatally-acquired HIV
• Use of any of the following medications within 7 days prior to study entry:

• St. John's wort (Hypercium perforatum)
• Anticonvulsants (eg, oxacarbazepine, phenobarbital, phenytoin)
• Anti-infectives (eg, rifabutin, rifampin, rifapentine)
• Corticosteroids (eg, dexamethasone (more than 1 dose))
• Proton pump inhibitors (eg, esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole)

Step 2

• Plans to start immunomodulators, topical imiquimod, HIV vaccine, systemic cytotoxic chemotherapy, or investigational therapy during Step 2 of the study
• Plans to initiate hepatitis C treatment during Step 2 of the study

NOTE: Please refer to the protocol for detailed eligibility criteria.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role: collaborator

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NETWORK

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jonathan Li, M.D., M.M.S.

Role: STUDY_CHAIR

Brigham and Women's Hospital Therapeutics (BWHT) CRS

Locations

31788 Alabama CRS

Birmingham, Alabama, United States

801 University of California, San Francisco HIV/AIDS CRS

San Francisco, California, United States

Whitman Walker Health CRS (31791)

Washington D.C., District of Columbia, United States

The Ponce de Leon Ctr. CRS (5802)

Atlanta, Georgia, United States

Northwestern University CRS (2701)

Chicago, Illinois, United States

Rush Univ. Med. Ctr. ACTG CRS (2702)

Chicago, Illinois, United States

IHV Baltimore Treatment CRS (4651)

Baltimore, Maryland, United States

Massachusetts General Hospital ACTG CRS (101)

Boston, Massachusetts, United States

Brigham and Women's Hosp. ACTG CRS (107)

Boston, Massachusetts, United States

University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787)

Rochester, New York, United States

Bronx-Lebanon Hosp. Ctr. CRS (31469)

The Bronx, New York, United States

Unc Aids Crs (3201)

Chapel Hill, North Carolina, United States

Moses H. Cone Memorial Hospital CRS (3203)

Greensboro, North Carolina, United States

University of Cincinnati CRS (2401)

Cincinnati, Ohio, United States

Metro Health CRS (2503)

Cleveland, Ohio, United States

Hosp. of the Univ. of Pennsylvania CRS (6201)

Philadelphia, Pennsylvania, United States

Pitt CRS (1001)

Pittsburgh, Pennsylvania, United States

The Miriam Hosp. ACTG CRS (2951)

Providence, Rhode Island, United States

Houston AIDS Research Team CRS (31473)

Houston, Texas, United States

Countries

United States

Related Links

http://rsc.tech-res.com/safetyandpharmacovigilance/

Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Version 1.0, December 2004 (Clarification, August 2009)

http://rsc.tech-res.com/safetyandpharmacovigilance/

Requirements, definitions, and methods for expedited reporting of Adverse Events (AEs) in Version 2.0 of the DAIDS EAE Manual

Other Identifiers

1U01AI068636

Identifier Type: NIH

Identifier Source: secondary_id

View Link

ACTG A5308

Identifier Type: -

Identifier Source: org_study_id